Roche Diagnostics Operations, Inc.

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Andreas Gallusser

Christoph Seidel

Juergen Spinke

Dieter Heindl

Herbert Von Der Eltz

Michael Schraeml

Georg Hess

Andrea Horsch

Dietmar Zdunek

Michael Grol

Volker Klemt

Klaus Hallermayer

Anneliese Borgya

Alfons Nichtl

Thomas Meier

Rolf Deeg

Christa Hubner-Parajsz

Rosemarie Kientsch-Engel

Martin Kaufmann

Hartmut Schetters

A binding agent of the Formula A-a':a-S-b:b&#x2032;-B:X(n), wherein A as well as B is a monovalent binder, a&#x2032;:a as well as b:b&#x2032; is a binding pair wherein a&#x2032; and a do not interfere with the binding of b to b&#x2032; and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a&#x2032;, a, b, b&#x2032; or S, (n) is an integer and at least 1, &#x2014; represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof.

Binding agent

The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. The epitopes recognized by the antibodies can slightly overlap.

Analytical sandwich test for determining NT-proBNP

The present invention relates to antibodies specifically binding to native proBNP, a method for specific detection of native proBNP, a method of correlating the level of native proBNP to the diagnosis of heart failure, a kit for detection of native proBNP and to a hybridoma cell line producing an antibody to native proBNP.

Method of detecting a subfraction of proBNP

The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. One of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 38 to 50. In addition, one of these antibodies is directed at least against parts of the epitope of NT-proBNP comprising the amino acids 1 to 37 or 43 to 76. The epitope recognized by the antibodies can slightly overlap.

Method of detecting native proBNP

The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.

Monoclonal antibodies against a human act and serine protease complex

Growing community of inventors

Penzberg, Germany

Andreas Gallusser